FIELD: biotechnology.
SUBSTANCE: invention discloses a set of polynucleotides, a set of vectors, an isolated cell and methods of producing an antigen-binding polypeptide structure using said vectors.
EFFECT: this group of inventions enables to obtain heterodimer antigen binding structures based on IgG immunoglobulin, including bispecific antibodies, with low output of the erroneously paired heterodimer.
34 cl, 19 dwg, 35 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING POLYPEPTIDE CONSTRUCTS CONTAINING KAPPA AND LAMBDA LIGHT CHAINS, AND APPLICATIONS THEREOF | 2016 |
|
RU2824193C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
